Venus Remedies Ltd Share Price
(VENUSREM)
₹284.6
as on 12:53PM, 26 Mar 2025
Venus Remedies Performance
Day's Low
Day's High
₹284.15Day's Price Range₹29652 Week's Low
52 Week's High
₹270.2552-Week Price Range₹427.9
| Returns % | |
| 1 Month Return | -4.61 % |
| 3 Month Return | -4.91 % |
| 1 Year Return | -6.62 % |
| Market Stats | |
| Previous Close | ₹290.70 |
| Open | ₹284.60 |
| Volume | 45.75K |
| Upper Circuit | ₹348.80 |
| Lower Circuit | ₹232.60 |
| Market Cap | ₹388.58Cr |
Venus Remedies Fundamentals
P/E Ratio
11.15
PEG Ratio
2.56
Market Cap
₹388.58 Cr
P/B Ratio
0.86
EPS
21.31
Dividend Yield
0Sector
Pharmaceuticals
ROE
6.18
Key events for Venus Remedies Ltd
Venus Remedies Partners for MET-X Development - 25 Feb, 2025
Venus Remedies has entered an exclusive licensing agreement with Infex Therapeutics to develop MET-X, targeting drug-resistant Gram-negative bacteria. The company will lead clinical trials in India, aiming for market entry by 2031-2032.Venus Remedies Secures Marketing Authorisation in Indonesia - 10 Feb, 2025
Venus Remedies gained nearly 3% after receiving marketing authorisation for its anticoagulant Enoxaparin in Indonesia, Southeast Asia's largest pharmaceutical market.Venus Remedies Reports Strong Q3 Results, Hits Upper Circuit - 05 Feb, 2025
Venus Remedies Ltd reported impressive Q3 results, with standalone net sales up 31.48% YoY and net profit soaring 194.02%. The stock hit a 20% upper circuit after a 186.13% increase in consolidated net profit. Additionally, a remarkable 458% QoQ profit increase was noted, highlighting strong financial performance.
Insights on Venus Remedies Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 3 quarters, 1.22 Cr → 19.6 Cr (in ₹), with an average increase of 73.7% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 110.2 Cr → 188.8 Cr (in ₹), with an average increase of 21.9% per quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 56.91% to 57.13% in Dec 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 41.76% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.9% return, outperforming this stock by 134.5%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 72.2% return, outperforming this stock by 78.9%
NEGATIVE IMPACTPrice Dip
In the last 3 months, VENUSREM stock has moved down by -4.9%
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 1.18% to 1.11% in Dec 2024 quarter
Venus Remedies Financials
Venus Remedies Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 41.76% | 0.00 | |
| Foreign Institutions | 1.11% | ||
| Mutual Funds | 0% | 0.00 | |
| Retail Investors | 57.13% | 0.38 | |
| Others | 0% |
Venus Remedies Key Indicators
Venus Remedies Valuation
Venus Remedies in the last 5 years
Lowest (-45.34x)
September 23, 2020
Today (11.15x)
March 25, 2025
Industry (54.31x)
March 25, 2025
Highest (21.70x)
December 28, 2023
Venus Remedies Earnings and Dividends
Venus Remedies Ltd Earnings Results
Venus Remedies Ltd’s net profit jumped 186.13% since last year same period to ₹19.60Cr in the Q3 2024-2025. On a quarterly growth basis, Venus Remedies Ltd has generated 458.4% jump in its net profits since last 3-months.
Read More about Earnings Results
Venus Remedies Technicals Summary
Bearish
Neutral
Bullish
Venus Remedies Ltd is currently in a Bearish trading position according to technical analysis indicators.
Venus Remedies Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| NA | ₹388.58 Cr | 232.78% | 0.54 | ₹28 Cr | ₹601 Cr | |
| NA | ₹4,992.12 Cr | 11.51% | 0.79 | -₹388 Cr | ₹75 Cr | |
| NA | ₹104.00 Cr | -3.08% | 0.60 | NA | NA | |
| NA | ₹71.57 Cr | 150.49% | 0.80 | NA | NA | |
| NA | ₹276.72 Cr | 23.25% | 0.60 | ₹5 Cr | ₹173 Cr |
About Venus Remedies
Revenue: ₹176.86Cr as on December 2024 (Q4 24)
Net Profit: ₹19.60Cr as on December 2024 (Q4 24)
Listing date: 20 Dec, 2006
Chairperson Name: Pawan Chaudhary
| Organisation | Venus Remedies |
| Headquarters | Panchkula |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Venus Remedies Ltd
What is Venus Remedies Ltd price today?
Venus Remedies Ltd share price today stands at ₹284.6, Open: ₹284.6, Previous Close: ₹290.7, High: ₹296, Low: ₹284.15, 52 Week High: ₹427.9, 52 Week Low: ₹270.25.
How to Buy Venus Remedies Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Venus Remedies Ltd shares
What are today's traded volumes of Venus Remedies Ltd?
Today's traded volume of Venus Remedies Ltd(VENUSREM) is 45.75K.
What is today's market capitalisation of Venus Remedies Ltd?
Today's market capitalisation of Venus Remedies Ltd(VENUSREM) is ₹388.58Cr.
What is the 52 Week High and Low Range of Venus Remedies Ltd?
How much percentage Venus Remedies Ltd is down from its 52 Week High?
Venus Remedies Ltd (VENUSREM) share price is ₹284.6. It is down -33.49% from its 52 Week High price of ₹427.9
How much percentage Venus Remedies Ltd is up from its 52 Week low?
Venus Remedies Ltd (VENUSREM) share price is ₹284.6. It is up 5.31% from its 52 Week Low price of ₹270.25